While an association between ERG expression and age and serum PSA levels has been observed in previous studies [13, 28] this association is unlikely to reflect prostate cancer biology since the relative frequency of the TMPRSS2:ERG fusions appears to be similar across early stage and metastatic prostate cancer, implying there is no selection of this molecular subtype with progression [29, 30]. This evidence concerns the gene TMPRSS2 and metastatic prostate carcinoma.